The TRUPCR® Acute Leukemia Panel Kit is intended for the qualitative detection & differentiation of 18 diagnostic and prognostic markers of Acute Myelogenous Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in peripheral blood samples using real-time PCR.
Key Features:
- Comprehensive detection and differentiation of 18 diagnostic and prognostic markers for ALL and AML
- Sample Type – EDTA Blood / Bone Marrow
- All Inclusive Kit as all reagents for cDNA chemistry, PCR and real-time PCR are included
- Sensitivity to detect up to 10 copies of fusion transcripts (AML1-ETO, CBFB-MYH11, BCR-ABL1, PML-RARA, E2A-PBX1, TEL-AML1, MLL-AF4, MLL-ENL, MLL-AF9, MLL-AF6, MLL-AF10, RBM15-MKL1, DEK-CAN and SET-CAN) and to 1% mutant allele in background of 99% wild type allele for C-KIT, NPM1 and FLT3-D835, I836 & ITD and to 5% mutant allele in background of 95% wild type allele IDH1/2
- Compatible Instruments – Applied Biosystems™ 7500 series / StepOne series / QuantStudio® series, Rotor-Gene Q, Bio-Rad CFX96, CFX384, AriaMx Real-Time PCR, Roche - LightCycler® 480 – II, Line gene K Real-Time PCR
Mutation Variants detected by TRUPCR® Acute Leukemia Panel Kit
| Gene | Variant | Technique | Requirement |
|---|---|---|---|
| CBFB-MYH11 | Type A | Reverse Transcription Real-Time PCR | RNA |
| Type E | |||
| Type D | |||
| BCR-ABL1 | e13a2 & e14a2 (p210) | ||
| e1a2 (p190) | |||
| e19a2(p230) | |||
| PML-RARA | BCR1 | ||
| BCR2 | |||
| BCR3 | |||
| AML1-ETO | RUNX1-RUNX1T1 | ||
| E2A-PBX1 | RUNX1-RUNX1T1 | ||
| TEL-AML1 | BCL2L14-RUNX1 | ||
| MLL-AF4 | MLL_AF4_e10-e4 | ||
| MLL_AF4_e9-e4 | |||
| MLL_AF4_e9-e5 | |||
| MLL_AF4_e11-e4 | |||
| MLL_AF4_e9-e6 | |||
| MLL-ENL | MLL_ENL_e9-e2 | ||
| MLL_ENL_e10-e2 | |||
| MLL-AF9 | MLL_AF9_e8-e9 | ||
| MLL_AF9_e8-e10 | |||
| MLL_AF9_e10-e6 | |||
| MLL-AF6 | MLL_AF6_e9-e2 | ||
| MLL-AF10 | MLL_AF10_e9-e4 | ||
| RBM15-MKL1 | RBM15_MKL1_e1-e5 | ||
| DEK-CAN | DEK_CAN_e9-e18 | ||
| SET-CAN | SET_CAN_e7-e18 | ||
| C-KIT | D816V | Real-Time PCR | DNA |
| NPM1 | Type A | ||
| Type B | |||
| Type D | |||
| FLT3 | TKD (D835Y, D835V, D835H & I836) | ||
| IDH1 | R132H, R132C , R132S, R132G, R132L, R132V & R100Q | ||
| IDH2 | R140W, R140Q, R172K, R172S, R172S, R172M, R172G &R172W |
Leukemia is defined as neoplastic proliferation of abnormal white blood cells (WBCs) and Acute Myeloid Leukemia (AML) is a group of hematological diseases, phenotypic and genetically heterogeneous, characterized by clonal expansion of myeloid precursors with diminished capacity for differentiation. AML represents 15 to 20% of acute leukemia cases in children and 80% in adults. Acute Lymphoblastic Leukemia (ALL) is mainly a disease of childhood that arises from recurrent genetic alterations that block precursor B- and T-cell differentiation and drive aberrant cell proliferation and survival. Usually one or more molecular abnormalities are found in acute leukemias and because of this configure a strong prognostic factor within the WHO classification. Currently molecular markers are considered as the most important markers for disease classification, risk stratification and treatment of leukemia patients.
Ordering Information:
| CAT. NO. | PRODUCT | CONTENTS |
|---|---|---|
| 3B1406 | TRUPCR® Acute Leukemia Panel Kit | 24 Reactions |
| 3B1407 | TRUPCR® Acute Leukemia Panel Kit | 48 Reactions |
